EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Trends in consumption and use of antidepressants and benzodiazepines in the Republic of Serbia in the period 2006-2019

Aleksandar Medarević

Glasnik javnog zdravlja · 2022

DOI: 10.5937/serbjph2202126m ↗
AbstractBibliografische Angaben

Abstract

Introduction: Antidepressants and benzodiazepines are used for the pharmacological treatment of mental illness with complementary therapies, with their global use showing an increasing trend. Aim: The aim of the study is to examine trends in the use of antidepressants and benzodiazepines in Serbia for the period 2006-2019. Method: Annual data on consumption were taken from the Serbian Medicines Agency and expressed in defined daily doses per 1000 inhabitants per day (DDD / TID). Consumption trends were analysed using segmented regression. Segmented regression calculates the average annual percentage change (AAPC) in consumption during the observed period from 2006 to 2019. Results: Consumption of antidepressants and benzodiazepines in 2019 were 35 DDD / TID and 126 DDD / TID, with percentage increases of 360% and 33% compared to 2006 and with AAPC values of 11.8 (p < 0.001) and 0.7 (p = 0.564) respectively. Among antidepressants, selective serotonin reuptake inhibitors were the most widely used. Anxiolytics-derivatives of benzodiazepines (N06BA) were the most used group among benzodiazepines. Bromazepam and Lorazepam had the highest volume in the N06BA group. Benzodiazepine-related drugs (Zolpidem) also had a growing trend, especially from 2006 to 2009. Conclusion: Use of benzodiazepines and antidepressants in Serbia increased, following global trends.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →